27 results on '"Urtishak, Karen A."'
Search Results
2. Sensitive detection of copy number alterations in samples with low circulating tumor DNA fraction.
3. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
4. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia
5. KMT2A partner genes in infant acute lymphoblastic leukemia have prognostic significance and correlate with age, white blood cell count, sex, and central nervous system involvement: a Children’s Oncology Group P9407 trial study
6. Abstract 4133: High prevalence and heterogeneity of emergence of BRCA reversion mutations at progression on niraparib treatment in BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) patients
7. Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
8. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial
9. Potent obatoclax cytotoxicity and activation of triple death mode killing across infant acute lymphoblastic leukemia
10. Unique Familial MLL(KMT2A)-Rearranged Precursor B-Cell Infant Acute Lymphoblastic Leukemia in Non-twin Siblings
11. Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease
12. Association of detectable levels of circulating tumor DNA (ctDNA) with disease burden in prostate cancer (PC).
13. Downregulation of Gene Expression with Negatively Charged Peptide Nucleic Acids (PNAs) in Zebrafish Embryos
14. Association of plasma DNA repair deficient (DRD) status with clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (AA) plus prednisone/dexamethasone (+P/D).
15. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia
16. Genome-wide TOP2A DNA cleavage is biased toward translocated and highly transcribed loci
17. Unique FamilialMLL(KMT2A)-Rearranged Precursor B-Cell Infant Acute Lymphoblastic Leukemia in Non-twin Siblings
18. PI3K/AKT/mTOR Signaling Is a Significant Druggable Pathway In Infant Acute Lymphoblastic Leukemia (ALL)
19. Predicting Clinical Dose-Exposure and Exposure-Response Relationships of Pan-Antiapoptotic BCL-2 Family Inhibitor Obatoclax in MLL Rearranged Infant Leukemias From Preclinical Disease Models and Adult Experience
20. Mechanisms in Leukemia-Associated Chromosomal Translocations: Novel, High-Throughput Sequencing Method to Detect Topoisomerase II (TOP2) Cleavage Complexes Genome-Wide with Exact Base Resolution,
21. Unique Familial MLL-rearranged Precursor B Cell Infant Acute Lymphoblastic Leukemia (ALL) in Non-Twin Siblings
22. Infant Acute Lymphoblastic Leukemias Are Pan-Sensitive to Obatoclax Across molecular/Cytogenetic Subtypes, Especially MLL-ENL, and gene Expression Profiles Determine Obatoclax IC50: A Report on the Children's Oncology Group (COG) P9407 Trial
23. Timeless Maintains Genomic Stability and Suppresses Sister Chromatid Exchange during Unperturbed DNA Replication
24. ATR and H2AX Cooperate in Maintaining Genome Stability under Replication Stress
25. Targeted gene knockdown in zebrafish using negatively charged peptide nucleic acid mimics
26. Activity of N-(Phenethyl)phenylethanolamines at β1 and β2 Adrenoceptors: Structural Modifications Can Result in Selectivity for Either Subtype
27. Activity of N-(Phenethyl)phenylethanolamines at β[sub 1] and β[sub 2] Adrenoceptors: Structural Modifications Can Result in Selectivity for Either Subtype.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.